AquADEKs2

Trial Status: 
Current Trial - Enrollment Complete

A Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients 

Purpose:

The purpose of this study in Cystic Fibrosis will be to further evaluate the effects of a modified formulation of AquADEKs® (AquADEKs-2) on markers of inflammation, antioxidant levels, and oxidative stress.

Eligibility:

You may be eligible if you are over 12 years of age, have cystic fibrosis, and have pancreatic insufficiency.

Sponsor:

Cystic Fibrosis Foundation Therapeutics

Principal Investigator: 

Cori Daines, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

 

Principal Investigator: 
Research Area: 
Clinical and Population Research